Enablex en es it fr

Enablex Brand names, Enablex Analogs

Enablex Brand Names Mixture

  • Cystosol W 3% Hexitols (Mannitol + Sorbitol)
  • Sorbitol Mannitol Irrigation (Mannitol + Sorbitol)

Enablex Chemical_Formula


Enablex RX_link


Enablex fda sheet

Enablex FDA

Enablex msds (material safety sheet)

Enablex Synthesis Reference

No information avaliable

Enablex Molecular Weight

426.55 g/mol

Enablex Melting Point

No information avaliable

Enablex H2O Solubility

No information avaliable

Enablex State


Enablex LogP


Enablex Dosage Forms

Extended-release tablets (containing 7.5 mg or 15 mg darifenacin as hydrobromide salt)

Enablex Indication

For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Enablex Pharmacology

Darifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.

Enablex Absorption

The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.

Enablex side effects and Toxicity

Overdosage can potentially result in severe central anticholinergic effects.

Enablex Patient Information

Enablex Organisms Affected

Humans and other mammals